World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
45
Citations
9396
World Ranking
4978
National Ranking
1930

Gaston Picchio publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Gaston Picchio sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 265 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 234 scientists 205–214 publications: 208 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 146 publications — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Gaston Picchio D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Gaston Picchio sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 112 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 123 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 94 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 45 D-Index — 10th percentile

10% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Gaston Picchio is affiliated with Johnson & Johnson in the United States and has contributed extensively to the field of medical research, with a strong focus on hepatitis viruses and liver disease. Their work spans various aspects of infectious diseases, especially hepatitis B and C viruses, and incorporates molecular biology, epidemiology, immunology, and antiviral therapies.

Picchio's research output includes numerous publications in high-impact journals. Notable papers include:

  • Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B (2022, Hepatology Communications)
  • Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells (2022, Journal of Hepatology)
  • Measuring hepatitis B pgRNA stability using an updated automated HBV pgRNA assay with increased sensitivity (2023, Hepatology Communications)
  • Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects (2022, Journal of Hepatology)
  • Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB) (2022, Journal of Hepatology)

The scholar frequently publishes in the following venues:

  • Journal of Hepatology
  • Hepatology Communications
  • Antiviral Research
  • Journal of Antimicrobial Chemotherapy
  • Annals of Hepatology

Frequent coauthors include:

  • Emily P. Thi
  • Timothy Eley
  • Karen Sims
  • Michael J. Sofia
  • Edward Gane

Throughout their career, Picchio has focused on several key topics:

  • Hepatitis B Virus Studies
  • Hepatitis C virus research
  • Liver Disease Diagnosis and Treatment
  • Viral gastroenteritis research and epidemiology
  • RNA Interference and Gene Delivery
  • Immunotherapy and Immune Responses
  • Immunodeficiency and Autoimmune Disorders

Their main fields of study center on Medicine, with subfields including Epidemiology, Hepatology, Infectious Diseases, Immunology, and Molecular Biology. This multidisciplinary approach supports an in-depth exploration of liver-related viral infections and immune system interactions.

Best Publications

  • Telaprevir for retreatment of HCV infection.

    Stefan Zeuzem;Pietro Andreone;Stanislas Pol;Eric Lawitz

  • TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

    Hilde Azijn;Ilse Tirry;Johan Vingerhoets;Marie-Pierre de Béthune

  • Establishment of B-Cell Lymphoma Cell Lines Persistently Infected with Hepatitis C Virus In Vivo and In Vitro: the Apoptotic Effects of Virus Infection

    Vicky M.-H. Sung;Shigetaka Shimodaira;Alison L. Doughty;Gaston R. Picchio

  • Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.

    Magali Bouvier-Alias;Keyur Patel;Harel Dahari;Stéphanie Beaucourt

  • Neutralizing Antibodies Have Limited Effects on the Control of Established HIV-1 Infection In Vivo

    Pascal Poignard;Rebecca Sabbe;Gaston R Picchio;Meng Wang

  • Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.

    Donald E. Mosier;Gastón R. Picchio;Richard J. Gulizia;Rebecca Sabbe

  • Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.

    Christine Katlama;Richard Haubrich;Jacob Lalezari;Adriano Lazzarin

  • Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies

    Johan Vingerhoets;Lotke Tambuyzer;Hilde Azijn;Annemie Hoogstoel

  • Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.

    Graham R. Foster;Christophe Hézode;Jean–Pierre Bronowicki;Giampiero Carosi

  • Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.

    Laurence Rimsky;Johan Vingerhoets;Veerle Van Eygen;Joseph Eron

  • Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials

    James C. Sullivan;Sandra De Meyer;Doug J. Bartels;Inge Dierynck

  • Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C

    Patrick Marcellin;Xavier Forns;Tobias Goeser;Peter Ferenci

  • hu-PBL-SCID mice: a model for human immune function, AIDS, and lymphomagenesis.

    Bruce E. Torbett;Gaston Picchio;Donald E. Mosier

  • Resistance profile of darunavir: combined 24-week results from the POWER trials.

    Unknown

  • Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment

    Unknown

  • svr results of a once-daily regimen of simeprevir (tmc435) plus sofosbuvir (gs-7977) with or without ribavirin in cirrhotic and non-cirrhotic Hcv genotype 1 treatment-naïve and prior null responder patients: The Cosmos study : lb-3

    Ira M. Jacobson;Reem H. Ghalib;Maribel Rodriguez-torres;Zobair M. Younossi

  • Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.

    Unknown

  • Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.

    Tara L. Kieffer;Sandra De Meyer;Doug J. Bartels;James C. Sullivan

  • Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).

    Unknown

  • Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors

    Lotke Tambuyzer;Hilde Azijn;Laurence T Rimsky;Johan Vingerhoets

  • Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling.

    Unknown

  • Two Mechanisms for Human Immunodeficiency Virus Type 1 Inhibition by N-Terminal Modifications of RANTES

    Cristina Pastore;Gastón R Picchio;Francesco Galimi;Richard Fish

  • Comparative Evaluation of the Total Hepatitis C Virus Core Antigen, Branched-DNA, and Amplicor Monitor Assays in Determining Viremia for Patients with Chronic Hepatitis C during Interferon Plus Ribavirin Combination Therapy

    Pascal Veillon;Christopher Payan;Gastón Picchio;Michèle Maniez-Montreuil

  • The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.

    Rima Kulkarni;Kerim Babaoglu;Eric B. Lansdon;Laurence Rimsky

  • Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.

    Markus Cornberg;Anna Suk-Fong Lok;Norah A Terrault;Fabien Zoulim

Frequent Co-Authors

Donald E. Mosier
Donald E. Mosier Scripps Research Institute
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Pedro Cahn
Pedro Cahn University of Buenos Aires
Ira M. Jacobson
Ira M. Jacobson New York University
Eric Lawitz
Eric Lawitz The University of Texas at Austin
Patrick Marcellin
Patrick Marcellin Université Paris Cité
Zobair M. Younossi
Zobair M. Younossi Inova Health System
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Bruce E. Torbett
Bruce E. Torbett Seattle Children's Hospital
Giampiero Carosi
Giampiero Carosi University of Brescia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens a variety of career paths, many of which intersect with health sciences and information management. For those interested in healthcare roles with a clinical focus, becoming a Functional Medicine Nurse Practitioner is a promising option, offering rewarding opportunities and competitive salaries. To learn more about this path, explore the functional medicine np salary insights.

Alternatively, if you have a knack for detail and coding, pursuing certification as a Professional Coder can lead to steady growth and valuable industry skills. The path to certification and expected earnings is detailed in the discussion about cpc.

Health Information Management (HIM) is another critical domain that combines healthcare with data management. A bachelor’s degree in this field enhances employability and earning potential, as noted in the overview of health information management bachelor degree salary.

For students seeking flexible learning options, numerous programs offer online HIM degrees accredited by CAHIIM. These accredited courses ensure quality training aligned with industry standards. Find top programs by checking the list of best online health information management degree cahiim accredited.

Best Scientists Citing Gaston Picchio

Trending Scientists

Recently Published Articles